Johnson & Johnson (NYSE:JNJ) recently presented promising data on TREMFYA® for ulcerative colitis and Crohn's disease, ...

New long-term extension data from the Phase IIb/III QUASAR trial demonstrate that Tremfya (guselkumab) maintains durable ...

Johnson & Johnson (NYSE: JNJ) today announced new data from the TREMFYA® (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to-severely active ulcerative colitis (UC ...

Johnson & Johnson announces new data from Tremfya phase 3 QUASAR LTE study in adults with moderately-to-severely active ulcerative colitis: San Diego, California Tuesday, May 6, 2 ...

Drug major Johnson & Johnson (JNJ) announced Monday positive new data from the Phase 3 ASTRO study evaluating TREMFYA (guselkumab) subcutaneous (SC) induction therapy ...

In ulcerative colitis (UC), Lilly’s Omvoh has taken ... reduction in BUF among Omvoh-treated patients. Meanwhile, J&J’s Tremfya has secured US approval for UC, but EU approval remains pending ...

Eli Lilly has the results it was looking for in a second, confirmatory trial of its anti-IL-23p19 antibody mirikizumab in ulcerative colitis as ... IL-23p19 antibody Tremfya (guselkumab), which ...

Hunter Renfrow is mounting an NFL comeback after spending the 2024 season out of the league battling ulcerative colitis. Here ...

Renfrow spent the 2024 season dealing with complications from an ulcerative colitis diagnosis. The autoimmune disease left the 29-year-old feeling lethargic as he battled high fevers and ...

CHARLOTTE, N.C. -- Wide receiver Hunter Renfrow dropped from 185 pounds to 150 pounds last year while being treated for ulcerative colitis, which played a big role in his decision to step away ...

In this Healio video, Edward L. Barnes, MD, MPH, associate professor of medicine, co-director of the Multidisciplinary IBD Center and associate fellowship program director at the University of North ...